Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT
Eltrombopag vs. Recombinant Human Thrombopoietin to Increase Platelet Level After Hematopoietic Stem Cell Transplantation: a Non-inferiority, Open-label, Randomized-controlled Study
Sponsor: Shenzhen Second People's Hospital
Listed as NCT03515096, this PHASE3 trial focuses on Eltrombopag and Hematopoietic Stem Cell Transplantation and remains completed. Sponsored by Shenzhen Second People's Hospital, it has been updated 10 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Sep 2021 — Apr 2022 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Apr 2019 — Aug 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shenzhen Second People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .